Skip to content
10-Q

Quarterly Report

Bioventus Inc. BVS

0001665988-26-000027

← back to feed
Filed
May 6, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 28, 2026 70.01M sh
Shares Diluted Q1 2026 · Mar 29, 2025 66.01M sh
Capex Q1 2026 · Mar 28, 2026 $574K
Capex Q1 2026 · Mar 29, 2025 $826K
Operating Cash Flow Q1 2026 · Mar 28, 2026 $8.93M
Operating Cash Flow Q1 2026 · Mar 29, 2025 −$19.33M
Long Term Debt Q1 2026 · Mar 28, 2026 $253.33M
Long Term Debt Q1 2026 · Dec 31, 2025 $278.95M
Short Term Debt Q1 2026 · Mar 28, 2026 $18.75M
Short Term Debt Q1 2026 · Dec 31, 2025 $15M
Cash And Equivalents Q1 2026 · Mar 28, 2026 $35.85M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $51.24M
Stockholders Equity Q1 2026 · Mar 28, 2026 $188.9M
Stockholders Equity Q1 2026 · Dec 31, 2025 $184.11M
Current Liabilities Q1 2026 · Mar 28, 2026 $148.1M
Current Liabilities Q1 2026 · Dec 31, 2025 $160.38M
Total Liabilities Q1 2026 · Mar 28, 2026 $416.27M
Total Liabilities Q1 2026 · Dec 31, 2025 $455.11M
Current Assets Q1 2026 · Mar 28, 2026 $249.81M
Current Assets Q1 2026 · Dec 31, 2025 $272.84M
Total Assets Q1 2026 · Mar 28, 2026 $650.54M
Total Assets Q1 2026 · Dec 31, 2025 $683.56M
Eps Diluted Q1 2026 · Mar 28, 2026 $0.04
Eps Diluted Q1 2026 · Mar 29, 2025 −$0.04
Eps Basic Q1 2026 · Mar 28, 2026 $0.05
Eps Basic Q1 2026 · Mar 29, 2025 −$0.04
Sga Expense Q1 2026 · Mar 28, 2026 $78.33M
Sga Expense Q1 2026 · Mar 29, 2025 $73.5M
Rd Expense Q1 2026 · Mar 28, 2026 $2.47M
Rd Expense Q1 2026 · Mar 29, 2025 $3.01M
Net Income Q1 2026 · Mar 28, 2026 $3.11M
Net Income Q1 2026 · Mar 29, 2025 −$2.64M
Operating Income Q1 2026 · Mar 28, 2026 $8.42M
Operating Income Q1 2026 · Mar 29, 2025 $4.87M
Gross Profit Q1 2026 · Mar 28, 2026 $90.77M
Gross Profit Q1 2026 · Mar 29, 2025 $83.06M
Cost Of Revenue Q1 2026 · Mar 28, 2026 $41.32M
Cost Of Revenue Q1 2026 · Mar 29, 2025 $40.82M
Revenue Q1 2026 · Mar 28, 2026 $132.09M
Revenue Q1 2026 · Mar 29, 2025 $123.88M